GeoVax Labs, Inc. (GOVXW)

Overview

GeoVax Labs, Inc. is a clinical-stage biotechnology firm focused on the development of human vaccines and immunotherapies for a broad spectrum of infectious diseases and solid tumor cancers. Utilizing its proprietary modified vaccinia ankara virus-like particle vaccine platform, GeoVax is at the forefront of addressing some of the most pressing health challenges of our time. With a history dating back to its incorporation in 1988, GeoVax has established itself in the biotechnology industry, headquartered in Smyrna, Georgia. Through strategic collaborations and partnerships with notable institutions such as the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the U.S. Department of Defense, Emory University, and the Burnet Institute, GeoVax leverages significant expertise and resources in its vaccine development programs.

Products and Services

• GEO-CM04S1

A leading vaccine candidate developed by GeoVax, GEO-CM04S1 is currently undergoing a Phase 2 clinical trial aimed at preventing COVID-19. This represents the company's response to the global pandemic and highlights its capabilities in rapidly developing relevant vaccine candidates.

• Gedeptin

A novel patented product/technology designed for treating solid tumors, with a specific focus on advanced head and neck squamous cell carcinoma. Gedeptin is in a Phase 1/2 clinical trial, underlining GeoVax's commitment to extending its research and development into cancer immunotherapy.

• GEO-CM02

Reflecting GeoVax's commitment to addressing coronaviruses broadly, GEO-CM02 is a pan-coronavirus vaccine candidate, embodying the company's forward-looking approach in preparing for future coronavirus outbreaks.

• GEO-ZM02

Currently in preclinical trial, GEO-ZM02 targets the Zika virus, contributing to the global effort to combat Zika and prevent its devastating impacts, particularly in pregnant women and their unborn children.

• GEO-MM02

This candidate is aimed at the treatment of malaria, a disease that continues to cause significant morbidity and mortality worldwide, especially in developing countries. GEO-MM02 signifies GeoVax's endeavor to tackle historically challenging infectious diseases.

• Other Infectious Disease Vaccines

GeoVax is also developing vaccines for several other infectious diseases, including treatments for hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa (GEO-LM01). These efforts exemplify the company's broad and impactful approach to vaccine development.